ArticleInflammation2000
Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice.
Article in Inflammation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- The immunomodulatory effects of lactoferrin and its derived peptides on NF-κB signaling pathway: A systematic review and meta-analysis.Immunity, inflammation and disease · 2023Pooled it
- Yolkin tempers inflammatory mediator release and liver pathology in experimental endotoxemia in mice.Histology and histopathology · 2026Article
- Challenges and Opportunities in Quantifying Bioactive Compounds in Human Breastmilk.Biomolecules · 2025Review
- Dietary Bovine Lactoferrin Reduces the Deleterious Effects of Lipopolysaccharide Injection on Mice Intestine.Nutrients · 2024Article
- Network analysis identifies a gene biomarker panel for sepsis-induced acute respiratory distress syndrome.BMC medical genomics · 2023Article
- Time to Kill and Time to Heal: The Multifaceted Role of Lactoferrin and Lactoferricin in Host Defense.Pharmaceutics · 2023Review
- The Lactoferrin Phenomenon-A Miracle Molecule.Molecules (Basel, Switzerland) · 2022Review
- Identification and profiling of Trichinella spiralis circulating antigens and proteins in sera of mice with trichinellosis.PloS one · 2022Article
- Stealthy microbes: HowFrontiers in cellular and infection microbiology · 2022Review
- Temporal Dynamics of T Helper Populations in the Proximal Small Intestine after Oral Bovine Lactoferrin Administration in BALB/c Mice.Nutrients · 2021Article
- The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.International immunopharmacology · 2021Review
- Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications.Frontiers in immunology · 2021Review
- Role of Human Milk Bioactives on Infants' Gut and Immune Health.Frontiers in immunology · 2021Review
- Lactoferrin as potential preventative and adjunct treatment for COVID-19.International journal of antimicrobial agents · 2020Review
- Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.Science advances · 2020Article
- Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections.International journal of molecular sciences · 2017Review
- Lactoferrin in a Context of Inflammation-Induced Pathology.Frontiers in immunology · 2017Review
- Bovine lactoferrin free of lipopolysaccharide can induce a proinflammatory response of macrophages.BMC veterinary research · 2016Article
- Effect of Polysaccharides from Acanthopanax senticosus on Intestinal Mucosal Barrier of Escherichia coli Lipopolysaccharide Challenged Mice.Asian-Australasian journal of animal sciences · 2016Article
- Clinical Potential of Hyperbaric Pressure-Treated Whey Protein.Healthcare (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypothesis that lactoferrin protects mice against lethal effects of bacterial lipopolysaccharide (LPS) is the subject of experimental investigations described in this article. Lipopolysaccharide is a powerful toxin produced by gram negative bacteria that when injected into humans or experimental animals reproduce many of the pathophysiologic and immune responses caused by live bacteria. Lactoferrin administered intraperitoneally 1 hr prior to injection of LPS significantly enhanced the survival of mice, reducing LPS-induced mortality from 83.3% to 16.7%. Changes in locomotor and other behavioral activities resulting from LPS injection were not present in mice treated with lactoferrin. Also, histological examination of intestine revealed remarkable resistance to injury produced by LPS if mice were pretreated with lactoferrin. Severe villus atrophy, edema and epithelial vacuolation were observed in LPS-treated animals but not in lactoferrin-treated counterparts. Electrophysiological parameters were used to assess secretory and absorptive functions in the small intestine. In mice treated with LPS, transmural electrical resistance was reduced and absorption of glucose was increased. Lactoferrin treatment had no significant influence on basal electrophysiological correlates of net ion secretion or glucose absorption nor on changes induced by LPS. Collectively, these results suggest that lactoferrin attenuates the lethal effect of LPS and modulates behavioral and histopathological sequela of endotoxemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.